ClinicalTrials.gg
CompletedNCT01665924Updated Mar 28, 2013

Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

A Phase 1 interventional study of GLPG0634 100mg capsule once a day for 10 days in Healthy, sponsored by Galapagos NV. Completed at 1 site in Belgium. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-28.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the amount of compound present in the blood (pharmacokinetics) after single and of multiple doses of GLPG0634 in elderly healthy subjects.

During the course of the study, the effect of aging on the pharmacokinetics as well as the effects of GLPG0634 on mechanism of action-related parameters in the blood (pharmacodynamics) will be assessed and the safety of multiple oral doses of GLPG0634 in elderly healthy subjects will be characterized.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female, age 40 years and older
  • between 18-30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any condition that might interfere with the procedures or tests in this study
  • Drug or alcohol abuse
  • Smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    40-50 years old

    GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old

    Drug: GLPG0634 100mg capsule once a day for 10 days

  • Experimental
    65-74 years old

    GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old

    Drug: GLPG0634 100mg capsule once a day for 10 days

  • Experimental
    75 years and older

    GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older

    Drug: GLPG0634 100mg capsule once a day for 10 days

06

What researchers measure

Primary outcomes

  1. The amount of GLPG0634 in plasma over time after single and multiple doses of GLPG0634

    To characterize the amount of GLPG0634 in plasma over time - pharmacokinetics (PK) - after single and multiple oral doses in different age groups, including elderly healthy subjects, thereby assessing the effect of aging

    Time frame: From predose (before first study drug administration) up to 72 hours post last study drug administration

Secondary outcomes

  1. The amount of GLPG0634 mechanism-of-action-related biomarkers in blood after multiple doses of GLPG0634

    To characterize the effects of GLPG0634 on mechanism of action-related biomarkers in the blood over time - pharmacodynamics (PD) - after multiple oral doses in different age groups, including elderly healthy subjects, thereby assessing the effect of aging

    Time frame: From predose (before first study drug administration) up to 24 hours post last study drug administration

  2. Number of adverse events

    To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of the number of adverse events reported

    Time frame: From screening up to 10 days after the last study drug administration

  3. Changes in vital signs as measured by heart rate, blood pressure and body temperature

    To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in vital signs as measured by heart rate, blood pressure and body temperature reported

    Time frame: From screening up to 10 days after the last study drug administration

  4. Changes in 12-lead ECG measures

    To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in 12-ECG measures reported

    Time frame: From screening up to 10 days after the last study drug administration

  5. Changes in physical exam measures

    To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in physical examination reported

    Time frame: From screening up to 10 days after the last study drug administration

  6. Changes in blood safety lab parameters

    To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in blood safety lab parameters assessed

    Time frame: From screening up to 10 days after the last study drug administration

  7. Changes in urine safety lab parameters

    To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in urine safety lab parameters assessed

    Time frame: From screening up to 10 days after the last study drug administration

07

Study locations

1 site
  • SGS LSS Clinical Pharmacology Unit Antwerp
    Antwerp, 2060, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2012
First posted
Aug 16, 2012
Start
Jul 2012
Primary completionActual
Sep 2012
CompletionActual
Oct 2012
Last update
Mar 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01665924
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Aug 16, 2012
Start date
Jul 2012
Primary completion
Sep 2012
Completion
Oct 2012
Last update
Mar 28, 2013

Study contacts

Frédéric Vanhoutte, MD
study director · Galapagos NV
Magdalena Petkova, MD
principal investigator · SGS LSS Clinical Pharmacology Unit Antwerp

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion